This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
News|Articles|March 20, 2024
- Drug Topics March 2024
- Volume 168
- Issue 02
OTC Product Roundup: Women's Health
Author(s)Lauren Biscaldi, MS
These OTC products are recommended to address a variety of symptoms associated with women's health issues.
Advertisement
READ MORE:
Articles in this issue
over 2 years ago
Adaptation Is the Key to Successover 2 years ago
Navigating Pediatric ADHD Medication Shortagesover 2 years ago
Focus On Obesity Management Before Addressing Comorbiditiesover 2 years ago
Vaccines to Watch in 2024Advertisement
Related to this article
Pharmacist-backed picks help families manage fever and pain, seasonal allergies, and cough and congestion as kids head back to the classroom.
Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.
Pharmacist Stephanie Young Moss explains menopause symptoms, hormone therapy guidance, and how pharmacists can expand menopause care access.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
3
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
4
Pharmacists Step Up on Test-To-Treat This American Pharmacist Month
5